<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SPRYCEL
                         - dasatinib tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SPRYCEL safely and effectively. See full prescribing information for SPRYCEL.<br><br><br>SPRYCEL<span class="Sup">®</span> (dasatinib) Tablet for Oral Use
	<br>Initial U.S. Approval: 2006</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions,
										<br>         <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span> <a href="#Section_5.6"> (5.6)</a>   10/2011 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><span class="Bold">SPRYCEL is a kinase inhibitor indicated for the treatment of</span> </p>
<ul class="Disc">
<li>newly diagnosed adults with Philadelphia chromosome-positive (Ph+) <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) in chronic phase. The trial is ongoing and further data will be required to determine long-term outcome. <a href="#Section_1">(1</a>, <a href="#Section_14">14)</a>
</li>
<li>adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. <a href="#Section_1">(1</a>, <a href="#Section_14">14)</a>
</li>
<li>adults with Philadelphia chromosome-positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (Ph+ ALL) with resistance or intolerance to prior therapy. <a href="#Section_1">(1</a>, <a href="#Section_14">14)</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Chronic phase CML: 100 mg once daily. <a href="#Section_2">(2)</a>
</li>
<li>Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL: 140 mg once daily. <a href="#Section_2">(2)</a>
</li>
</ul>
<p class="Highlighta">Administered orally, with or without a meal. Tablets should not be crushed or cut. <a href="#Section_2">(2)</a> </p>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. <a href="#Section_3">(3</a>, <a href="#Section_16">16)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. <a href="#Section_4">(4)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:</span> Severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> may occur and require dose interruption or reduction. Monitor complete blood counts regularly. <a href="#Section_2.3">(2.3</a>, <a href="#Section_5.1">5.1</a>, <a href="#Section_6.1">6.1)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Related Events (mostly associated with severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>):</span> CNS and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhages</span>, including fatalities, have occurred. Severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> may require treatment interruptions and transfusions. Use SPRYCEL
with caution in patients requiring medications that inhibit platelet function or anticoagulants. <a href="#Section_5.2">(5.2</a>, <a href="#Section_6.1">6.1)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>:</span> SPRYCEL is associated with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, sometimes severe, including <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and pleural and <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusions</span>. Manage with appropriate supportive care measures. <a href="#Section_5.3">(5.3</a>, <a href="#Section_6.1">6.1)</a>
</li>
<li>
<span class="Italics">QT Prolongation:</span>  Use SPRYCEL with caution in patients who have or may develop prolongation of the QT interval. <a href="#Section_5.4">(5.4)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span> Monitor patients for signs and symptoms consistent with cardiac dysfunction and treat appropriately. <a href="#Section_5.5">(5.5</a>, <a href="#Section_6.1">6.1)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span> (PAH):</span> SPRYCEL may increase the risk of developing PAH which may be reversible on discontinuation. Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating SPRYCEL and during treatment. <a href="#Section_5.6">(5.6)</a>
</li>
<li>
<span class="Italics">Use in Pregnancy:</span> Fetal harm may occur when administered to a pregnant woman. Women should be advised of the potential hazard to the fetus and to avoid becoming pregnant. <a href="#Section_5.7">(5.7</a>, <a href="#Section_8.1">8.1)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥10%) in patients with newly diagnosed chronic phase CML included <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Most common adverse reactions (≥20%) in patients with resistance or intolerance to prior imatinib therapy included <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, 
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. <a href="#Section_6.1">(6.1)</a> </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">CYP3A4 Inhibitors:</span> May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. <a href="#Section_2.1">(2.1</a>, <a href="#Section_7.1">7.1)</a>
</li>
<li>
<span class="Italics">CYP3A4 Inducers:</span> May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. <a href="#Section_2.1">(2.1</a>, <a href="#Section_7.2">7.2)</a>
</li>
<li>
<span class="Italics">Antacids:</span> May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. <a href="#Section_7.2">(7.2)</a>
</li>
<li>
<span class="Italics">H<span class="Sub">2</span></span><span class="Italics"> Antagonists/Proton Pump Inhibitors:</span> May decrease dasatinib drug levels. Consider antacids in place of H<span class="Sub">2</span> antagonists or proton pump inhibitors. <a href="#Section_7.2">(7.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Use SPRYCEL with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <a href="#Section_8.6">(8.6)</a>
</li></ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1    INDICATIONS AND USAGE </a></h1>
<h1><a href="#section-2" class="toc">2    DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1   Dose Modification</a></h2>
<h2><a href="#section-2.2" class="toc">2.2   Dose Escalation</a></h2>
<h2><a href="#section-2.3" class="toc">2.3   Dose Adjustment for Adverse Reactions</a></h2>
<h1><a href="#section-3" class="toc">3    DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4    CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5     WARNINGS AND PRECAUTIONS  </a></h1>
<h2><a href="#section-5.1" class="toc">5.1   <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Related Events</a></h2>
<h2><a href="#section-5.3" class="toc">5.3   <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4   QT Prolongation</a></h2>
<h2><a href="#section-5.5" class="toc">5.5   <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6   <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7   Use in Pregnancy</a></h2>
<h1><a href="#section-6" class="toc">6    ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.2" class="toc">6.1   <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">Chronic Myeloid Leukemia</span> (CML)</a></h2>
<h2><a href="#section-6.3" class="toc">6.2   Philadelphia Chromosome-Positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> (Ph+ ALL)</a></h2>
<h2><a href="#section-6.4" class="toc">6.3   Additional Data From Clinical Trials</a></h2>
<h2><a href="#section-6.5" class="toc">6.4   Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7    DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1   Drugs That May Increase Dasatinib Plasma Concentrations</a></h2>
<h2><a href="#section-7.2" class="toc">7.2   Drugs That May Decrease Dasatinib Plasma Concentrations</a></h2>
<h2><a href="#section-7.3" class="toc">7.3   Drugs That May Have Their Plasma Concentration Altered By Dasatinib</a></h2>
<h1><a href="#section-8" class="toc">8    USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1   Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3   Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4   Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5   Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7   <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10    OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11    DESCRIPTION </a></h1>
<h1><a href="#section-11" class="toc">12    CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1   Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3   Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13    NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14    CLINICAL STUDIES </a></h1>
<h2><a href="#section-13.1" class="toc">14.1   Newly Diagnosed Chronic Phase CML</a></h2>
<h2><a href="#section-13.2" class="toc">14.2   Imatinib Resistant or Intolerant CML or Ph+ ALL</a></h2>
<h1><a href="#section-14" class="toc">15    REFERENCES </a></h1>
<h1><a href="#section-15" class="toc">16    HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-15.1" class="toc">16.1   How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2   Storage</a></h2>
<h2><a href="#section-15.3" class="toc">16.3   Handling and Disposal</a></h2>
<h1><a href="#section-16" class="toc">17    PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-16.1" class="toc">17.1   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2   <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3   <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4   Pregnancy</a></h2>
<h2><a href="#section-16.5" class="toc">17.5   Gastrointestinal Complaints</a></h2>
<h2><a href="#section-16.6" class="toc">17.6   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></a></h2>
<h2><a href="#section-16.7" class="toc">17.7   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></a></h2>
<h2><a href="#section-16.8" class="toc">17.8   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-16.9" class="toc">17.9   Lactose</a></h2>
<h2><a href="#section-16.10" class="toc">17.10   Missed Dose</a></h2>
<h2><a href="#section-17.1" class="toc">FDA-Approved Patient Labeling</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1    INDICATIONS AND USAGE </h1>
<p class="First">SPRYCEL<span class="Sup">®</span> (dasatinib) is indicated for the treatment of adults with</p>
<ul class="Disc">
<li>
								newly diagnosed Philadelphia chromosome-positive (Ph+) <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates <span class="Italics">[see Clinical Studies <a href="#Section_14.1">(14.1)</a>]</span>. The trial is ongoing and further data will be required to determine long-term outcome.
							</li>
<li>chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
						</li>
<li>Philadelphia chromosome-positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (Ph+ ALL) with resistance or intolerance to prior therapy.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2    DOSAGE AND ADMINISTRATION </h1>
<p class="First">The recommended starting dosage of SPRYCEL for chronic phase CML is 100 mg administered orally once daily. The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL is 140 mg administered orally once daily. Tablets should not be crushed or cut; they should be swallowed whole. SPRYCEL can be taken with or without a meal, either in the morning or in the evening.
						</p>
<p>In clinical studies, treatment with SPRYCEL was continued until disease progression or until no longer tolerated by the patient. The effect of stopping treatment after the achievement of a complete cytogenetic response (CCyR) has not been investigated.
						 </p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1   Dose Modification</h2>
<p class="First"><span class="Bold">Concomitant Strong CYP3A4 inducers: </span>The use of concomitant strong CYP3A4 inducers may decrease dasatinib plasma concentrations and should be avoided (eg, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital). St. John’s Wort may decrease dasatinib plasma concentrations unpredictably and should be avoided. If patients must be coadministered a strong CYP3A4 inducer, based on pharmacokinetic studies, a SPRYCEL dose increase should be considered. If the dose of SPRYCEL is increased, the patient should be monitored carefully for toxicity <span class="Italics">[see Drug Interactions <a href="#Section_7.2">(7.2)</a>]</span>.
								</p>
<p><span class="Bold">Concomitant Strong CYP3A4 inhibitors: </span>CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) may increase dasatinib plasma concentrations. Grapefruit juice may also increase plasma concentrations of dasatinib and should be avoided.
								</p>
<p>Selection of an alternate concomitant medication with no or minimal enzyme inhibition potential, if possible, is recommended. If SPRYCEL must be administered with a strong CYP3A4 inhibitor, a dose decrease should be considered.  Based on pharmacokinetic
studies, a dose decrease to 20 mg daily should be considered for patients taking SPRYCEL 100 mg daily. For patients taking SPRYCEL 140 mg daily, a dose decrease to 40 mg daily should be considered. These reduced doses of SPRYCEL are predicted to adjust the area under the curve (AUC) to the range observed without CYP3A4 inhibitors. However, there are no clinical data with these dose adjustments in patients receiving strong CYP3A4 inhibitors. If SPRYCEL is not tolerated after dose reduction, either the strong CYP3A4 inhibitor must be discontinued, or SPRYCEL should be stopped until treatment with the inhibitor has ceased. When the strong inhibitor is discontinued, a washout period of approximately 1 week should be allowed before the SPRYCEL dose is increased. <span class="Italics">[See Drug Interactions <a href="#Section_7.1">(7.1)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2   Dose Escalation</h2>
<p class="First">In clinical studies of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 180 mg once daily (advanced phase CML and Ph+ ALL) was allowed in patients who did not achieve a hematologic or cytogenetic response at the recommended starting dosage.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3   Dose Adjustment for Adverse Reactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.1"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h3>
<p class="First">In clinical studies, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was managed by dose interruption, dose reduction, or discontinuation of study
therapy. Hematopoietic growth factor has been used in patients with resistant <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Guidelines for dose modifications are summarized in Table
1.
										</p>
<a name="i12a51b17-9592-4c32-81e9-2e442c0d93f6"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 1: Dose Adjustments for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></caption>
<colgroup>
<col width="25%">
<col width="25%">
<col width="50%">
</colgroup>
<tfoot><tr class="First Last"><td align="left" colspan="3" rowspan="1">* ANC: absolute neutrophil count</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" colspan="1" rowspan="3">Chronic Phase CML<br>(starting dose 100 mg once daily) </td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="3">ANC* &lt;0.5 × 10<span class="Sup">9</span>/L<br>or<br>Platelets &lt;50 × 10<span class="Sup">9</span>/L </td>
<td class="Toprule" align="left" colspan="1" rowspan="1">1. Stop SPRYCEL until ANC ≥1.0 × 10<span class="Sup">9</span>/L and platelets ≥50 × 10<span class="Sup">9</span>/L.</td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">2. Resume treatment with SPRYCEL at the original starting dose if recovery occurs in ≤7 days. </td></tr>
<tr><td class="Botrule" align="left" colspan="1" rowspan="1">
														3. If platelets &lt;25 × 10<span class="Sup">9</span>/L or recurrence of ANC &lt;0.5 × 10<span class="Sup">9</span>/L for &gt;7 days, repeat Step 1 and resume SPRYCEL at a reduced dose of 80 mg once daily for second episode. For third episode, further reduce dose to 50 mg once daily (for newly diagnosed patients) or discontinue SPRYCEL (for patients resistant or intolerant to prior therapy including imatinib).
													</td></tr>
<tr>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="4">Accelerated Phase CML,<br> Blast Phase CML and<br> Ph+ ALL<br>(starting dose 140 mg once daily)</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="4">ANC* &lt;0.5 × 10<span class="Sup">9</span>/L<br>or<br>Platelets &lt;10 × 10<span class="Sup">9</span>/L</td>
<td align="left" colspan="1" rowspan="1">1. Check if <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> is related to <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (marrow aspirate or biopsy). </td>
</tr>
<tr><td align="left" colspan="1" rowspan="1">2. If <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> is unrelated to <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, stop SPRYCEL until ANC ≥1.0 × 10<span class="Sup">9</span>/L and platelets ≥20 × 10<span class="Sup">9</span>/L and resume at the original starting dose.</td></tr>
<tr><td align="left" colspan="1" rowspan="1">
														3. If recurrence of <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span>, repeat Step 1 and resume SPRYCEL at a reduced dose of 100 mg once daily (second episode) or 80 mg once daily (third episode).
													</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="1" rowspan="1">
														4. If <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> is related to <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, consider dose escalation to 180 mg once daily.
													</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.2"></a><a name="section-2.3.2"></a><p></p>
<h3>Non-hematological adverse reactions</h3>
<p class="First">If a severe non-hematological adverse reaction develops with SPRYCEL use, treatment must be withheld until the event has resolved or improved. Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the initial severity of the event.
										</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3    DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">SPRYCEL (dasatinib) Tablets are available as 20-mg, 50-mg, 70-mg, 80-mg, 100-mg, and 140-mg white to off-white, biconvex, film-coated tablets. <span class="Italics">[See How Supplied <a href="#Section_16.1">(16.1)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4    CONTRAINDICATIONS </h1>
<p class="First">None.
						</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5     WARNINGS AND PRECAUTIONS  </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1   <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Treatment with SPRYCEL is associated with severe (NCI CTC Grade 3 or 4) <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.
Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. In a dose-optimization study in patients with resistance or intolerance to prior imatinib therapy and chronic phase CML, Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was reported less frequently in patients treated with 100 mg once daily than in patients treated with other dosing regimens.</p>
<p>Perform complete blood counts weekly for the first 2 months and then monthly thereafter, or as clinically indicated. <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> was generally reversible and usually managed by withholding SPRYCEL temporarily or dose reduction <span class="Italics">[see Dosage and Administration <a href="#Section_2.3">(2.3)</a></span> and <span class="Italics">Adverse Reactions <a href="#Section_6.1">(6.1)</a>]</span>. 
								 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Related Events</h2>
<p class="First">In addition to causing <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in human subjects, dasatinib caused platelet dysfunction <span class="Italics">in vitro</span>. In all clinical studies, severe central nervous system (CNS) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>, including fatalities, occurred in 1% of patients receiving SPRYCEL. Severe <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, including fatalities, occurred in 4% of patients and generally required treatment interruptions and transfusions. Other cases of severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> occurred in 2% of patients. Most <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events were associated with severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
								</p>
<p>Patients were excluded from participation in initial SPRYCEL clinical studies if they took medications that inhibit platelet function or anticoagulants. In subsequent trials, the use of anticoagulants, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) was allowed concurrently with SPRYCEL if the platelet count was &gt;50,000–75,000 per microliter. Exercise caution if patients are required to take medications that inhibit platelet function or anticoagulants.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3   <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">SPRYCEL is associated with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. In clinical trials, severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> was reported in up to 10% of patients. <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> were each reported in &lt;1% of patients. Severe <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> was reported in 1% of patients. Patients who develop symptoms suggestive of <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span>, should be evaluated by chest X-ray. Severe <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> may require thoracentesis and oxygen therapy. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> events were typically managed by supportive care measures that include diuretics or short courses of steroids. In dose-optimization studies, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events were reported less frequently with once daily dosing than with other dosing regimens.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4   QT Prolongation</h2>
<p class="First"><span class="Italics">In vitro</span> data suggest that dasatinib has the potential to prolong cardiac ventricular repolarization (QT interval). Of the 2440 patients with CML treated with SPRYCEL in clinical studies, 15 patients (&lt;1%) had QTc prolongation reported as an adverse reaction. Twenty-two patients (1%) experienced a QTcF &gt;500 ms. In 865 patients with <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> treated with SPRYCEL in five Phase 2 single-arm studies, the maximum mean changes in QTcF (90% upper bound CI) from baseline ranged from 7.0 ms to 13.4 ms.
								</p>
<p>Administer SPRYCEL with caution to patients who have or may develop prolongation of QTc. These include patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, patients taking anti-arrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy. Correct <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> prior to SPRYCEL administration.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5   <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">
									Cardiac adverse reactions were reported in 5.8% of 258 patients taking SPRYCEL, including 1.6% of patients with <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> congestive, <span class="product-label-link" type="condition" conceptid="141038" conceptname="Diastolic dysfunction">diastolic dysfunction</span>, fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>.  Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6   <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SPRYCEL may increase the risk of developing <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH) which may occur anytime after initiation, including after more than one year of treatment. Manifestations include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. PAH may be reversible on discontinuation of SPRYCEL. Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating SPRYCEL and during treatment. If PAH is confirmed, SPRYCEL should be permanently discontinued.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7   Use in Pregnancy</h2>
<p class="First"> SPRYCEL may cause fetal harm when administered to a pregnant woman. In nonclinical studies, at plasma concentrations below those observed in humans receiving therapeutic doses of dasatinib, embryo-fetal toxicities, including skeletal malformations, were observed in rats and rabbits. There are no adequate and well-controlled studies of SPRYCEL in pregnant women. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with SPRYCEL <span class="Italics">[see Use in Specific Populations <a href="#Section_8.1">(8.1)</a>]</span>.
										</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6-para"></a><a name="section-6"></a><p></p>
<h1>6    ADVERSE REACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6"></a><a name="section-6.1"></a><p></p>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:
								</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see Dosage and Administration <a href="#Section_2.3">(2.3)</a></span> and <span class="Italics">Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span>.
									</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> related events <span class="Italics">[see Warnings and Precautions <a href="#Section_5.2">(5.2)</a>]</span>.
									</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> <span class="Italics">[see Warnings and Precautions <a href="#Section_5.3">(5.3)</a>]</span>.
									</li>
<li>QT prolongation <span class="Italics">[see Warnings and Precautions <a href="#Section_5.4">(5.4)</a>]</span>.
									</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>]</span>.
									</li>
<li><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span> <span class="Italics">[see Warnings and Precautions <a href="#Section_5.6">(5.6)</a>]</span>.</li>
</ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
								</p>
<p>The data described below reflect exposure to SPRYCEL in clinical studies including 258 patients with newly diagnosed chronic phase CML and in 2182 patients with imatinib resistant or intolerant CML or Ph+ ALL.</p>
<p>In the newly diagnosed chronic phase CML trial, the median duration of therapy was 18 months; the median average daily dose was 99 mg.</p>
<p>In the imatinib resistant or intolerant CML or Ph+ ALL clinical trials, patients had a minimum of 2 years follow-up (starting dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily). Among patients with chronic phase CML and resistance or intolerance to prior imatinib therapy, the median duration of treatment with SPRYCEL 100 mg once daily was 24 months (range 1–33 months). The median duration of treatment with SPRYCEL 140 mg once daily was 15 months (range 0.03–36 months) for accelerated phase CML, 3 months (range 0.03–29 months) for myeloid blast phase CML, and 3 months (range 0.1–10 months) for lymphoid blast CML. 
								</p>
<p>The majority of SPRYCEL-treated patients experienced adverse reactions at some time. In the newly diagnosed chronic phase CML trial, drug was discontinued for adverse reactions in 6% of SPRYCEL-treated patients. Among patients with resistance or intolerance to prior imatinib therapy, the rates of discontinuation for adverse reaction were 15% in chronic phase CML, 16% in accelerated phase CML, 15% in myeloid blast phase CML, 8% in lymphoid blast phase CML, and 8% in Ph+ ALL. In a dose-optimization study in patients with resistance or intolerance to prior imatinib therapy and chronic phase CML, the rate of discontinuation for adverse reaction was lower in patients treated with 100 mg once daily than in patients treated with other dosing regimens (10% and 16%, respectively).
								</p>
<p>The most frequently reported adverse reactions reported in ≥10% of patients in newly diagnosed chronic phase CML included <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events (<span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, superficial <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusions</span> were reported in 31 patients (see Table 2).</p>
<p>The most frequently reported adverse reactions reported in ≥20% of patients with resistance or intolerance to prior imatinib therapy included <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>,  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.
								</p>
<p>The most frequently reported serious adverse reactions in patients with newly diagnosed chronic phase CML included <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (2%), <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (2%), <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (1%), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (1%). The most frequently reported serious adverse reactions in patients with resistance or intolerance to prior imatinib therapy included <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (11%), <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> (4%),
<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (4%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (3%), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (3%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (3%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (2%), <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>/cardiac dysfunction (2%), <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> (1%), and CNS <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (1%).
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.2"></a><p></p>
<h2>6.1   <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">Chronic Myeloid Leukemia</span> (CML)</h2>
<p class="First">Adverse reactions (excluding laboratory abnormalities) that were reported in at least 10% of patients are shown in Table 2 for newly diagnosed patients with chronic phase CML and Table 3 for CML patients with resistance or intolerance to prior imatinib therapy.</p>
<a name="i3e670ddc-d238-4159-8bfe-39754f60ace6"></a><table border="0" cellpadding="1" cellspacing="1" frame="below" rules="none" width="100%">
<caption><span>Table 2: Adverse Reactions Reported in ≥10% of Patients with Newly Diagnosed Chronic Phase CML</span></caption>
<colgroup>
<col width="40%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
</colgroup>
<thead>
<tr class="First">
<th class="Toprule" valign="bottom"> </th>
<th class="Botrule Toprule" align="center" colspan="2"><span class="Bold">All Grades</span></th>
<th class="Botrule Lrule Toprule" align="center" colspan="2"><span class="Bold">Grade 3/4</span></th>
</tr>
<tr>
<th valign="bottom"> </th>
<th class="Botrule" valign="bottom">SPRYCEL<br>(n=258)</th>
<th class="Botrule" valign="bottom">Imatinib<br>(n=258)</th>
<th class="Botrule Lrule" valign="bottom">SPRYCEL<br>(n=258)</th>
<th class="Botrule" valign="bottom">Imatinib<br>(n=258)</th>
</tr>
<tr class="Last">
<th class="Botrule" align="center" colspan="1" valign="bottom"><span class="Bold">Preferred Term</span></th>
<th class="Botrule" align="center" colspan="4" valign="bottom"><span class="Bold">Percent (%) of Patients</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="5">
<span class="Sup">a</span> Includes <span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">cardiac failure acute</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">cardiac failure congestive</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="141038" conceptname="Diastolic dysfunction">diastolic dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> decreased, and <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>.</td></tr>
<tr><td colspan="5">
<span class="Sup">b</span> Includes <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">rash pustular</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin exfoliation</span>, and <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>.</td></tr>
<tr><td colspan="5">
<span class="Sup">c</span> Adverse reaction of special interest with &lt;10% frequency.</td></tr>
<tr class="Last"><td colspan="5">
<span class="Sup">d</span> Includes <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4096343" conceptname="Bleeding from ear">ear hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, intra-<span class="product-label-link" type="condition" conceptid="4342882" conceptname="Intra-abdominal hematoma">abdominal hematoma</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, scleral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></td>
<td align="center">23</td>
<td align="center">43</td>
<td class="Lrule" align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td align="center">12</td>
<td align="center">0</td>
<td class="Lrule" align="center">&lt;1</td>
<td align="center">0</td>
</tr>
<tr>
<td>    Superficial <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span></td>
<td align="center">10</td>
<td align="center">36</td>
<td class="Lrule" align="center">0</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">Generalized edema</span></td>
<td align="center">3</td>
<td align="center">7</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>/<br>        cardiac dysfunction<span class="Sup">a</span>
</td>
<td align="center">2</td>
<td align="center">1</td>
<td class="Lrule" align="center">&lt;1</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span></td>
<td align="center">2</td>
<td align="center">&lt;1</td>
<td class="Lrule" align="center">&lt;1</td>
<td align="center">0</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span></td>
<td align="center">&lt;1</td>
<td align="center">0</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">18</td>
<td align="center">19</td>
<td class="Lrule" align="center">&lt;1</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">12</td>
<td align="center">10</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td align="center">12</td>
<td align="center">16</td>
<td class="Lrule" align="center">0</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">b</span>
</td>
<td align="center">11</td>
<td align="center">17</td>
<td class="Lrule" align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">9</td>
<td align="center">21</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">8</td>
<td align="center">11</td>
<td class="Lrule" align="center">&lt;1</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">6</td>
<td align="center">12</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span><span class="Sup">c</span>
</td>
<td align="center">6</td>
<td align="center">5</td>
<td class="Lrule" align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span></td>
<td align="center">2</td>
<td align="center">&lt;1</td>
<td class="Lrule" align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td>    Other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Sup">d</span>
</td>
<td align="center">5</td>
<td align="center">5</td>
<td class="Lrule" align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td>    CNS <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td align="center">0</td>
<td align="center">&lt;1</td>
<td class="Lrule" align="center">0</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">5</td>
<td align="center">10</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">Muscle inflammation</span></td>
<td align="center">4</td>
<td align="center">19</td>
<td class="Lrule" align="center">0</td>
<td align="center">&lt;1</td>
</tr>
</tbody>
</table>
<br><a name="i55e9ba26-ab54-48fe-8635-de1e187bd006"></a><table border="0" cellpadding="1" cellspacing="1" frame="below" rules="none" width="100%">
<caption><span>Table 3: Adverse Reactions Reported in ≥10% of Patients with CML Resistant or Intolerant to Prior Imatinib Therapy</span></caption>
<colgroup>
<col width="28%">
<col width="8%">
<col width="8%">
<col width="9%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="9%">
<col width="8%">
</colgroup>
<thead>
<tr class="First">
<th class="Toprule" valign="bottom"> </th>
<th class="Toprule" align="center" colspan="2"><span class="Bold">100 mg Once Daily</span></th>
<th class="Botrule Lrule Toprule" align="center" colspan="6"><span class="Bold">140 mg Once Daily</span></th>
</tr>
<tr>
<th valign="bottom"> </th>
<th class="Toprule" align="center" colspan="2"><span class="Bold">Chronic<br>(n=165)</span></th>
<th class="Botrule Lrule Toprule" align="center" colspan="2"><span class="Bold">Accelerated<br>(n=157)</span></th>
<th class="Botrule Toprule" align="center" colspan="2"><span class="Bold">Myeloid Blast<br>(n=74)</span></th>
<th class="Botrule Toprule" align="center" colspan="2"><span class="Bold">Lymphoid Blast<br>(n=33)</span></th>
</tr>
<tr>
<th class="Botrule" rowspan="2"><span class="Bold">Preferred Term</span></th>
<th class="Toprule" align="center"><span class="Bold">All Grades</span></th>
<th class="Toprule" align="center"><span class="Bold">Grade 3/4</span></th>
<th class="Lrule" align="center"><span class="Bold">All Grades</span></th>
<th align="center"><span class="Bold">Grade 3/4</span></th>
<th><span class="Bold">All Grades</span></th>
<th><span class="Bold">Grade 3/4</span></th>
<th><span class="Bold">All Grades</span></th>
<th><span class="Bold">Grade 3/4</span></th>
</tr>
<tr class="Last"><th class="Botrule Toprule" align="center" colspan="8" valign="bottom"><span class="Bold">Percent (%) of Patients</span></th></tr>
</thead>
<tfoot>
<tr class="First"><td colspan="9">
<span class="Sup">a</span> Includes ventricular dysfunction, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">cardiac failure congestive</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4163710" conceptname="Dilated cardiomyopathy">congestive cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="141038" conceptname="Diastolic dysfunction">diastolic dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> decreased, and ventricular failure.</td></tr>
<tr class="Last"><td colspan="9">
<span class="Sup">b</span> Includes <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, erythrosis, exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, generalized <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, genital <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,  <span class="product-label-link" type="condition" conceptid="137627" conceptname="Prickly heat">heat rash</span>, <span class="product-label-link" type="condition" conceptid="4110715" conceptname="Milia">milia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> follicular, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">rash pustular</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin exfoliation</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, <span class="product-label-link" type="condition" conceptid="4032478" conceptname="Bullous urticaria">urticaria vesiculosa</span>, and <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></td>
<td align="center">34</td>
<td align="center">4</td>
<td class="Lrule" align="center">35</td>
<td align="center">8</td>
<td align="center">34</td>
<td align="center">7</td>
<td align="center">21</td>
<td align="center">6</td>
</tr>
<tr>
<td>   Superficial <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span></td>
<td align="center">18</td>
<td align="center">0</td>
<td class="Lrule" align="center">18</td>
<td align="center">1</td>
<td align="center">14</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td align="center">18</td>
<td align="center">2</td>
<td class="Lrule" align="center">21</td>
<td align="center">7</td>
<td align="center">20</td>
<td align="center">7</td>
<td align="center">21</td>
<td align="center">6</td>
</tr>
<tr>
<td>      <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">Generalized edema</span></td>
<td align="center">3</td>
<td align="center">0</td>
<td class="Lrule" align="center">1</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td>      <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td class="Lrule" align="center">3</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td>      <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>/<br>          cardiac dysfunction<span class="Sup">a</span>
</td>
<td align="center">0</td>
<td align="center">0</td>
<td class="Lrule" align="center">0</td>
<td align="center">0</td>
<td align="center">4</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td>      <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td class="Lrule" align="center">1</td>
<td align="center">0</td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">33</td>
<td align="center">1</td>
<td class="Lrule" align="center">27</td>
<td align="center">1</td>
<td align="center">18</td>
<td align="center">1</td>
<td align="center">15</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">27</td>
<td align="center">2</td>
<td class="Lrule" align="center">31</td>
<td align="center">3</td>
<td align="center">20</td>
<td align="center">5</td>
<td align="center">18</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">24</td>
<td align="center">2</td>
<td class="Lrule" align="center">19</td>
<td align="center">2</td>
<td align="center">20</td>
<td align="center">1</td>
<td align="center">9</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">20</td>
<td align="center">2</td>
<td class="Lrule" align="center">20</td>
<td align="center">3</td>
<td align="center">15</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td align="center">19</td>
<td align="center">2</td>
<td class="Lrule" align="center">11</td>
<td align="center">0</td>
<td align="center">8</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">18</td>
<td align="center">1</td>
<td class="Lrule" align="center">19</td>
<td align="center">1</td>
<td align="center">23</td>
<td align="center">1</td>
<td align="center">21</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span><span class="Sup">b</span>
</td>
<td align="center">17</td>
<td align="center">2</td>
<td class="Lrule" align="center">15</td>
<td align="center">0</td>
<td align="center">16</td>
<td align="center">1</td>
<td align="center">21</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">13</td>
<td align="center">0</td>
<td class="Lrule" align="center">7</td>
<td align="center">1</td>
<td align="center">7</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">12</td>
<td align="center">1</td>
<td class="Lrule" align="center">10</td>
<td align="center">0</td>
<td align="center">5</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> (including bacterial, <br>    viral, fungal, and<br>    non-specified)</td>
<td align="center">12</td>
<td align="center">1</td>
<td class="Lrule" align="center">10</td>
<td align="center">6</td>
<td align="center">14</td>
<td align="center">7</td>
<td align="center">9</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">12</td>
<td align="center">1</td>
<td class="Lrule" align="center">6</td>
<td align="center">0</td>
<td align="center">8</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td align="center">11</td>
<td align="center">1</td>
<td class="Lrule" align="center">26</td>
<td align="center">8</td>
<td align="center">19</td>
<td align="center">9</td>
<td align="center">24</td>
<td align="center">9</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td class="Lrule" align="center">8</td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">7</td>
<td align="center">9</td>
<td align="center">3</td>
</tr>
<tr>
<td>   CNS <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td class="Lrule" align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">7</td>
<td align="center">1</td>
<td class="Lrule" align="center">11</td>
<td align="center">1</td>
<td align="center">12</td>
<td align="center">0</td>
<td align="center">15</td>
<td align="center">0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">5</td>
<td align="center">1</td>
<td class="Lrule" align="center">11</td>
<td align="center">2</td>
<td align="center">18</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td class="Lrule" align="center">4</td>
<td align="center">4</td>
<td align="center">12</td>
<td align="center">12</td>
<td align="center">12</td>
<td align="center">12</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.1"></a><a name="section-6.2.1"></a><p></p>
<h3>Laboratory Abnormalities</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> was commonly reported in all patient populations. The frequency of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was higher in patients with advanced phase CML than in chronic phase CML (Tables 4 and 5). <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> was reported in patients with normal baseline laboratory values as well as in patients with pre-existing laboratory abnormalities.
										</p>
<p>In patients who experienced severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, recovery generally occurred following dose interruption or reduction; permanent discontinuation of treatment occurred in 2% of patients with newly diagnosed chronic phase CML and 5% of patients with resistance or intolerance to prior imatinib therapy <span class="Italics">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span>. 
										</p>
<p>Grade 3 or 4 elevations of transaminase or bilirubin and Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> were reported in patients with all phases of CML but were reported with an increased frequency in patients with myeloid or lymphoid blast phase CML. Elevations in transaminase or bilirubin were usually managed with dose reduction or interruption. Patients developing Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> during the course of SPRYCEL therapy often had recovery with oral calcium supplementation.
										</p>
<p>Laboratory abnormalities reported in patients with newly diagnosed chronic phase CML are shown in Table 4. There were no discontinuations of SPRYCEL therapy in this patient population due to biochemical laboratory parameters.</p>
<a name="i05a81f48-827f-4818-84a7-ba374d1ace2a"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 4: CTC Grade 3/4 Laboratory Abnormalities in Patients with Newly Diagnosed Chronic Phase CML</span></caption>
<colgroup>
<col width="40%">
<col width="30%">
<col width="30%">
</colgroup>
<thead>
<tr class="First">
<th class="Toprule"></th>
<th class="Botrule Toprule" align="center">SPRYCEL<br>(n=258)</th>
<th class="Botrule Lrule Toprule" align="center">Imatinib<br>(n=258)</th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" colspan="1" rowspan="1"> </th>
<th class="Botrule" align="center" colspan="2">Percent (%) of Patients</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3" valign="top">CTC grades: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (Grade 3 ≥0.5–&lt;1.0 × 10<span class="Sup">9</span>/L, Grade 4 &lt;0.5 × 10<span class="Sup">9</span>/L); <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (Grade 3 ≥25–&lt;50 × 10<span class="Sup">9</span>/L, Grade 4 &lt;25 × 10<span class="Sup">9</span>/L); <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (hemoglobin Grade 3 ≥65–&lt;80 g/L, Grade 4 &lt;65 g/L); elevated creatinine (Grade 3 &gt;3–6 × upper limit of normal range (ULN), Grade 4 &gt;6 × ULN); elevated bilirubin (Grade 3 &gt;3–10 × ULN, Grade 4 &gt;10 × ULN); elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> or SGPT (Grade 3 &gt;5–20 × ULN, Grade 4 &gt;20 × ULN); <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (Grade 3 &lt;7.0–6.0 mg/dL, Grade 4 &lt;6.0 mg/dL); <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> (Grade 3 &lt;2.0–1.0 mg/dL, Grade 4 &lt;1.0 mg/dL); <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (Grade 3 &lt;3.0–2.5 mmol/L, Grade 4 &lt;2.5 mmol/L).</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" colspan="1" rowspan="1"><span class="Bold">Hematology Parameters</span></td>
<td align="left" colspan="1" rowspan="1"> </td>
<td class="Lrule" align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td align="center" colspan="1" rowspan="1">22</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">20</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center" colspan="1" rowspan="1">19</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">10</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center" colspan="1" rowspan="1">11</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><span class="Bold">Biochemistry Parameters</span></td>
<td align="left" colspan="1" rowspan="1"> </td>
<td class="Lrule" align="left" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></td>
<td align="center" colspan="1" rowspan="1">5</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">24</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center">0</td>
<td class="Lrule" align="center">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td align="center" colspan="1" rowspan="1">3</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Elevated SGPT (ALT)</td>
<td align="center" colspan="1" rowspan="1">&lt;1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST)</td>
<td align="center" colspan="1" rowspan="1">&lt;1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Elevated Bilirubin</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">0</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">    Elevated Creatinine</td>
<td align="center" colspan="1" rowspan="1">&lt;1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">1</td>
</tr>
</tbody>
</table>
<p>Laboratory abnormalities reported in patients with CML resistant or intolerant to imatinib who received the recommended starting doses of SPRYCEL are shown by disease phase in Table 5.
										</p>
<a name="ic999ba9c-a9ce-4246-8f0b-7f80b1fea67f"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 5: CTC Grade 3/4 Laboratory Abnormalities in Clinical Studies of CML: Resistance or Intolerance to Prior Imatinib Therapy</span></caption>
<colgroup>
<col width="28%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="18%">
</colgroup>
<thead>
<tr class="First">
<th class="Toprule"></th>
<th class="Toprule"></th>
<th class="Botrule Lrule Toprule" align="center" colspan="3"><span class="Bold">Advanced Phase CML</span></th>
</tr>
<tr>
<th></th>
<th class="Botrule" align="center" colspan="1"><span class="Bold">Chronic Phase CML</span></th>
<th class="Botrule Lrule" align="center" colspan="3"><span class="Bold">140 mg Once Daily</span></th>
</tr>
<tr>
<th></th>
<th class="Botrule Toprule" align="center" valign="bottom">
<span class="Bold">100 mg Once Daily</span><br><span class="Bold">(n=165)</span>
</th>
<th class="Botrule Lrule Toprule" align="center" colspan="1" rowspan="1" valign="bottom">
<span class="Bold">Accelerated Phase</span><br><span class="Bold">(n=157)</span>
</th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1" valign="bottom">
<span class="Bold">Myeloid Blast Phase</span><span class="Bold"><br>(n=74)</span>
</th>
<th class="Botrule Toprule" align="center" valign="bottom">
<span class="Bold">Lymphoid Blast Phase</span><span class="Bold"><br>(n=33)</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" colspan="1" rowspan="1"> </th>
<th class="Botrule Toprule" align="center" colspan="4" rowspan="1"><span class="Bold"><span class="Bold">Percent (%) of Patients</span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5" valign="top">CTC grades: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (Grade 3 ≥0.5–&lt;1.0 × 10<span class="Sup">9</span>/L,
Grade 4 &lt;0.5 × 10<span class="Sup">9</span>/L); <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (Grade 3 ≥25–&lt;50 × 10<span class="Sup">9</span>/L, Grade 4 &lt;25 × 10<span class="Sup">9</span>/L); <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (hemoglobin Grade 3 ≥65–&lt;80 g/L, Grade 4 &lt;65 g/L); elevated creatinine (Grade 3 &gt;3–6 × upper limit of normal range (ULN), Grade 4 &gt;6 × ULN); elevated bilirubin (Grade 3 &gt;3–10 × ULN, Grade 4 &gt;10 × ULN); elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> or SGPT (Grade 3 &gt;5–20 × ULN, Grade 4 &gt;20 × ULN); <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (Grade 3 &lt;7.0–6.0 mg/dL, Grade 4 &lt;6.0 mg/dL); <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> (Grade 3 &lt;2.0–1.0 mg/dL, Grade 4 &lt;1.0 mg/dL); <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (Grade 3 &lt;3.0–2.5 mmol/L, Grade 4 &lt;2.5 mmol/L).</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" colspan="1" rowspan="1"><span class="Bold">Hematology Parameters</span></td>
<td align="left" colspan="1" rowspan="1"> </td>
<td class="Lrule" align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td align="center" colspan="1" rowspan="1">36</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">58</td>
<td align="center" colspan="1" rowspan="1">77</td>
<td align="center">79</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center" colspan="1" rowspan="1">23</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">63</td>
<td align="center" colspan="1" rowspan="1">78</td>
<td align="center">85</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center" colspan="1" rowspan="1">13</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">47</td>
<td align="center" colspan="1" rowspan="1">74</td>
<td align="center">52</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><span class="Bold">Biochemistry Parameters</span></td>
<td align="left" colspan="1" rowspan="1"> </td>
<td class="Lrule" align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1"> </td>
<td> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></td>
<td align="center" colspan="1" rowspan="1">10</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">13</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center">18</td>
</tr>
<tr>
<td>    <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center">2</td>
<td class="Lrule" align="center">7</td>
<td align="center">11</td>
<td align="center">15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td align="center" colspan="1" rowspan="1">&lt;1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">4</td>
<td align="center" colspan="1" rowspan="1">9</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Elevated SGPT (ALT)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">5</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST)</td>
<td align="center" colspan="1" rowspan="1">&lt;1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Elevated Bilirubin</td>
<td align="center" colspan="1" rowspan="1">&lt;1</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">3</td>
<td align="center">6</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">    Elevated Creatinine</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td class="Lrule" align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">8</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.3"></a><p></p>
<h2>6.2   Philadelphia Chromosome-Positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> (Ph+ ALL)</h2>
<p class="First">A total of 135 patients with Ph+ ALL were treated with SPRYCEL in clinical studies.  The median duration of treatment was 3 months (range 0.03–31 months). The safety profile of patients with Ph+ ALL was similar to those with lymphoid blast phase CML.  The most frequently reported adverse reactions included <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events, such as <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (24%) and superficial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (19%), and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (31%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (24%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (16%). <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> (19%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (17%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (16%), and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (16%) were also frequently reported. The most frequently reported serious adverse reactions included <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (11%), <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> (7%), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (6%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (5%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (4%), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (3%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2%), and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (2%). 
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.4"></a><p></p>
<h2>6.3   Additional Data From Clinical Trials</h2>
<p class="First">The following adverse reactions were reported in patients in the SPRYCEL clinical studies at a frequency of 1%–&lt;10%, 0.1%–&lt;1%, or &lt;0.1%. These events are included on the basis of clinical relevance. 
								</p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span></span><span class="Italics">1%–&lt;10% </span>– <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span> (including <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>/<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">neutropenic colitis</span>), <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral soft tissue disorder</span>; <span class="Italics">0.1%–&lt;1% </span>– <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span>, upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; <span class="Italics">&lt;0.1%</span> – protein losing gastroenteropathy.
								</p>
<p><span class="Bold"><span class="Bold Italics">General Disorders and Administration Site Conditions: </span></span><span class="Italics">1%–&lt;10% – </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>;<span class="Italics"> 0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, temperature intolerance.
								</p>
<p><span class="Bold"><span class="Bold Italics">Skin and Subcutaneous Tissue Disorders: </span></span><span class="Italics">1%–&lt;10% </span>– <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> (including <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>); <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation disorder</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, bullous conditions, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, <span class="product-label-link" type="condition" conceptid="4225434" conceptname="Acute febrile neutrophilic dermatosis">acute febrile neutrophilic dermatosis</span>, <span class="product-label-link" type="condition" conceptid="432719" conceptname="Panniculitis">panniculitis</span>, palmar-plantar erythrodysesthesia syndrome.
								 </p>
<p><span class="Bold Italics">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: </span><span class="Italics">1%–&lt;10% </span>– <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>; <span class="Italics">0.1%–&lt;1% </span>– <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; <span class="Italics">&lt;0.1%</span> – <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: </span></span><span class="Italics">1%–&lt;10%</span> – <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>; <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; <span class="Italics">&lt;0.1%</span> – <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, transient ischemic attack, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics">Blood and Lymphatic System Disorders: </span></span><span class="Italics">1%–&lt;10%</span> – <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; <span class="Italics">&lt;0.1%</span> – <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">aplasia pure red cell</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: </span></span><span class="Italics">1%–&lt;10% –</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>; <span class="Italics">0.1%–&lt;1% </span>– <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>; <span class="Italics">&lt;0.1% –</span> <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics">Investigations: </span></span><span class="Italics">1%–&lt;10%</span> – <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>; <span class="Italics">0.1%–&lt;1% </span>– <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span> increased.  
								</p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: </span></span><span class="Italics">1%–&lt;10% </span>– <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (including bacterial, viral, and fungal), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>/<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infection</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (including fatal outcomes).
								</p>
<p><span class="Bold"><span class="Bold Italics">Metabolism and Nutrition Disorders: </span></span><span class="Italics">1%–&lt;10%</span> – <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, appetite disturbances; <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>.
								 </p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: </span></span><span class="Italics">1%–&lt;10% </span>– <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>), <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>);<span class="Italics"> &lt;0.1%</span> – <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>. 
								</p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: </span></span><span class="Italics">1%–&lt;10%</span> – visual disorder (including <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, and <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span>), <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>;<span class="Italics"> 0.1% –&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.
								 </p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: </span></span><span class="Italics">1%–&lt;10% </span>– <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="Italics">&lt;0.1%</span> – <span class="product-label-link" type="condition" conceptid="4081096" conceptname="Livedo reticularis">livedo reticularis</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics">Psychiatric Disorders: </span></span><span class="Italics">1%–&lt;10%</span> – <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4197184" conceptname="Pseudobulbar affect">affect lability</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>.</p>
<p><span class="Bold"><span class="Bold Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: </span></span><span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstruation irregular</span>.
								 </p>
<p><span class="Bold"><span class="Bold Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications: </span></span><span class="Italics">1%–&lt;10%</span> – <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>.
								 </p>
<p><span class="Bold"><span class="Bold Italics">Ear and Labyrinth Disorders: </span></span><span class="Italics">1%–&lt;10% – </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>;<span class="Italics"> 0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics">Hepatobiliary Disorders: </span></span><span class="Italics">0.1%–&lt;1%</span> –  <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. 
								</p>
<p><span class="Bold"><span class="Bold Italics">Renal and Urinary Disorders: </span></span><span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics">Neoplasms Benign, Malignant, and Unspecified: </span></span><span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span>.
								</p>
<p><span class="Bold"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span></span><span class="Italics">0.1%–&lt;1%</span> – <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (including <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>).
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.4"></a><a name="section-6.5"></a><p></p>
<h2>6.4   Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions have been identified during post approval use of SPRYCEL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: </span><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/<span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>/<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> (including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>)</p>
<p><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7    DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1a"></a><a name="section-7.1"></a><p></p>
<h2>7.1   Drugs That May Increase Dasatinib Plasma Concentrations</h2>
<p class="First"><span class="Bold">CYP3A4 Inhibitors:</span>  Dasatinib is a CYP3A4 substrate. In a study of 18 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, 20-mg SPRYCEL once daily coadministered with 200 mg of ketoconazole twice daily increased the dasatinib C<span class="Sub">max</span> and AUC by four- and five-fold, respectively. Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 may increase exposure to dasatinib and should be avoided. In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided <span class="Italics">[see Dosage and Administration <a href="#Section_2.1">(2.1)</a>]</span>. 
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2   Drugs That May Decrease Dasatinib Plasma Concentrations</h2>
<p class="First"><span class="Bold">CYP3A4 Inducers:</span> When a single morning dose of SPRYCEL was administered following 8 days of continuous evening administration of 600 mg of rifampin, a potent CYP3A4 inducer, the mean C<span class="Sub">max</span> and AUC of dasatinib were decreased by 81% and 82%, respectively. Alternative agents with less enzyme induction potential should be considered. If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered <span class="Italics">[see Dosage and Administration <a href="#Section_2.1">(2.1)</a>]</span>.
								</p>
<p><span class="Bold">Antacids:</span> Nonclinical data demonstrate that the solubility of dasatinib is pH dependent. In a study of 24 healthy subjects, administration of 30 mL of aluminum hydroxide/magnesium hydroxide 2 hours prior to a single 50-mg dose of SPRYCEL was associated with no relevant change in dasatinib AUC; however, the dasatinib C<span class="Sub">max</span> increased 26%. When 30 mL of aluminum hydroxide/magnesium hydroxide was administered to the same subjects concomitantly with a 50-mg dose of SPRYCEL, a 55% reduction in dasatinib AUC and a 58% reduction in C<span class="Sub">max</span> were observed. Simultaneous administration of SPRYCEL with antacids should be avoided. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL. 
								</p>
<p><span class="Bold">H<span class="Sub">2</span> Antagonists/Proton Pump Inhibitors:</span>  Long-term suppression of gastric acid secretion by H<span class="Sub">2</span> antagonists or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure. In a study of 24 healthy subjects, administration of a single 50-mg dose of SPRYCEL 10 hours following famotidine reduced the AUC and C<span class="Sub">max</span> of dasatinib by 61% and 63%, respectively. In a study of 14 healthy subjects, administration of a single 100-mg dose of SPRYCEL 22 hours following a 40-mg omeprazole dose at steady state reduced the AUC and C<span class="Sub">max</span> of dasatinib by 43% and 42%, respectively. The concomitant use of H<span class="Sub">2</span> antagonists or proton pump inhibitors with SPRYCEL is not recommended. The use of antacids (at least 2 hours prior to or 2 hours after the dose of SPRYCEL) should be considered in place of H<span class="Sub">2</span> antagonists or proton pump inhibitors in patients receiving SPRYCEL therapy. 
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3   Drugs That May Have Their Plasma Concentration Altered By Dasatinib</h2>
<p class="First"><span class="Bold">CYP3A4 Substrates:</span>  Single-dose data from a study of 54 healthy subjects indicate that the mean C<span class="Sub">max</span> and AUC of simvastatin, a CYP3A4 substrate, were increased by 37% and 20%, respectively, when simvastatin was administered in combination with a single 100-mg dose of SPRYCEL. Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL. 
								</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8    USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1   Pregnancy</h2>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category D</h3>
<p class="First">SPRYCEL may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of SPRYCEL in pregnant women. Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant. If SPRYCEL is used during pregnancy, or if the patient becomes pregnant while taking SPRYCEL, the patient should be apprised of the potential hazard to the fetus.
										</p>
<p>In nonclinical studies, at plasma concentrations below those observed in humans receiving therapeutic doses of dasatinib, embryo-fetal toxicities were observed in rats and rabbits. <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal death</span> was observed in rats. In both rats and rabbits, the lowest doses of dasatinib tested (rat: 2.5 mg/kg/day [15 mg/m<span class="Sup">2</span>/day] and rabbit: 0.5 mg/kg/day [6 mg/m<span class="Sup">2</span>/day]) resulted in embryo-fetal toxicities. These doses produced maternal AUCs of 105 ng•hr/mL (0.3-fold the human AUC in females at a dose of 70 mg twice daily) and 44 ng•hr/mL (0.1-fold the human AUC) in rats and rabbits, respectively. Embryo-fetal toxicities included skeletal malformations at multiple sites (scapula, humerus, femur, radius, ribs, and clavicle), reduced ossification (sternum; thoracic, lumbar, and sacral vertebrae; forepaw phalanges; pelvis; and hyoid body), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and microhepatia.
										</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3   Nursing Mothers</h2>
<p class="First">It is unknown whether SPRYCEL is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from SPRYCEL, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
								</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4   Pediatric Use</h2>
<p class="First">The safety and efficacy of SPRYCEL in patients less than 18 years of age have not been established.
								</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5   Geriatric Use</h2>
<p class="First">In the newly diagnosed chronic phase CML study, 25 patients (10%) were 65 years of age and over and 7 patients (3%) were 75 years of age and over. Of the 2182 patients in clinical studies of SPRYCEL with resistance or intolerance to imatinib therapy, 547 (25%) were 65 years of age and over and 105 (5%) were 75 years of age and over. No differences in efficacy were observed between older and younger patients. Compared to patients under age 65 years, patients aged 65 years and older are more likely to experience toxicity.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of dasatinib was evaluated in healthy volunteers with normal
liver function and patients with moderate (Child-Pugh class B) and severe (Child-Pugh class C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Compared to the healthy volunteers with normal hepatic function, the dose normalized pharmacokinetic parameters were decreased in the patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
<p>No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>. Caution is recommended when administering SPRYCEL to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7   <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">There are currently no clinical studies with SPRYCEL in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Less than 4% of dasatinib and its metabolites are excreted via the kidney.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10    OVERDOSAGE </h1>
<p class="First">Experience with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of SPRYCEL in clinical studies is limited to isolated cases. Overdosage of 280 mg per day for 1 week was reported in two patients and both developed severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Since SPRYCEL is associated with severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> <span class="Italics">[see Warnings and Precautions </span><span class="Italics"><a href="#Section_5.1">(5.1)</a></span> and <span class="Italics">Adverse Reactions </span><span class="Italics"><a href="#Section_6.1">(6.1)</a>]</span>, patients who ingested more than the recommended dosage should be closely monitored for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and given appropriate supportive treatment.
						</p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdose</span> in animals was associated with cardiotoxicity. Evidence of cardiotoxicity included ventricular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and valvular/ventricular/atrial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> at single doses ≥100 mg/kg (600 mg/m<span class="Sup">2</span>) in rodents. There was a tendency for increased systolic and diastolic blood pressure in monkeys at single doses ≥10 mg/kg (120 mg/m<span class="Sup">2</span>).
						</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11    DESCRIPTION </h1>
<p class="First">SPRYCEL (dasatinib) is a kinase inhibitor. The chemical name for dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate. The molecular formula is C<span class="Sub">22</span>H<span class="Sub">26</span>ClN<span class="Sub">7</span>O<span class="Sub">2</span>S • H<span class="Sub">2</span>O, which corresponds to a formula weight of 506.02 (monohydrate). The anhydrous free base has a molecular weight of 488.01. Dasatinib has the following chemical structure:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f&amp;name=sprycel-struct.jpg"></div>
<p>Dasatinib is a white to off-white powder. The drug substance is insoluble in water and slightly soluble in ethanol and methanol. SPRYCEL tablets are white to off-white, biconvex, film-coated tablets containing dasatinib, with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium dioxide, and polyethylene glycol.
						</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12    CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1   Mechanism of Action</h2>
<p class="First">Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. </p>
<p><span class="Italics">In vitro</span>, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) and <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> gene overexpression.
									 </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3   Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.1"></a><a name="section-11.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Maximum plasma concentrations (C<span class="Sub">max</span>) of dasatinib are observed between 0.5 and 6 hours  (T<span class="Sub">max</span>) following oral administration. Dasatinib exhibits dose proportional increases in AUC and linear elimination characteristics over the dose range of 15 mg to 240 mg/day. The overall mean terminal half-life of dasatinib is 3–5 hours.
										</p>
<p>Data from a study of 54 healthy subjects administered a single, 100-mg dose of dasatinib 30 minutes following consumption of a high-fat meal resulted in a 14% increase in the mean AUC of dasatinib. The observed food effects were not clinically relevant.
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.2"></a><a name="section-11.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">In patients, dasatinib has an apparent volume of distribution of 2505 L, suggesting that the drug is extensively distributed in the extravascular space. Binding of dasatinib and its active metabolite to human plasma proteins <span class="Italics">in vitro</span> was approximately 96% and 93%, respectively, with no concentration <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> over the range of 100–500 ng/mL.
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.3"></a><a name="section-11.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. CYP3A4 was the primary enzyme responsible for the formation of the active metabolite. Flavin-containing monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites. 
										</p>
<p>The exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 5% of the dasatinib AUC. This indicates that the active metabolite of dasatinib is unlikely to play a major role in the observed pharmacology of the drug. Dasatinib also had several other inactive oxidative metabolites.
										</p>
<p>Dasatinib is a weak time-dependent inhibitor of CYP3A4. At clinically relevant concentrations, dasatinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1. Dasatinib is not an inducer of human CYP enzymes. 
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.4"></a><a name="section-11.2.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">Elimination is primarily via the feces. Following a single oral dose of [<span class="Sup">14</span>C]-labeled dasatinib, approximately 4% and 85% of the administered radioactivity was recovered in the urine and feces, respectively, within 10 days. Unchanged dasatinib accounted for 0.1% and 19% of the administered dose in urine and feces, respectively, with the remainder of the dose being metabolites.
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.5"></a><a name="section-11.2.5"></a><p></p>
<h3>Effects of Age and Gender</h3>
<p class="First">Pharmacokinetic analyses of demographic data indicate that there are no clinically relevant effects of age and gender on the pharmacokinetics of dasatinib.
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6"></a><a name="section-11.2.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">Dasatinib doses of 50 mg and 20 mg were evaluated in eight patients with moderate (Child-Pugh class B) and seven patients with severe (Child-Pugh class C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, respectively. Matched controls with normal hepatic function (n=15) were also evaluated and received a dasatinib dose of 70 mg. Compared to subjects with normal liver function, patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had decreases in dose normalized C<span class="Sub">max</span> and AUC by 47% and 8%, respectively. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had dose normalized C<span class="Sub">max</span> decreased by 43% and AUC decreased by 28% compared to the normal controls.
										</p>
<p>These differences in C<span class="Sub">max</span> and AUC are not clinically relevant. Dose adjustment is not necessary in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
										</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13    NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"> In a two-year carcinogenicity study, rats were administered oral doses of dasatinib at 0.3, 1, and 3 mg/kg/day. The highest dose resulted in a plasma drug exposure (AUC) level equivalent to human exposure at 70 mg twice daily. Dasatinib induced a statistically significant increase in the combined incidence of squamous cell carcinomas and <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> in the uterus and cervix of high-dose females and <span class="product-label-link" type="condition" conceptid="4052054" conceptname="Benign adenoma of prostate">prostate adenoma</span> in low-dose males.</p>
<p>Dasatinib was clastogenic when tested <span class="Italics">in vitro</span> in Chinese hamster ovary cells, with and without metabolic activation. Dasatinib was not mutagenic when tested in an <span class="Italics">in vitro</span> bacterial cell assay (Ames test) and was not genotoxic in an <span class="Italics">in vivo</span> rat micronucleus study.
								</p>
<p>The effects of dasatinib on male and female fertility have not been studied. However, results of repeat-dose toxicity studies in multiple species indicate the potential for dasatinib to impair reproductive function and fertility. Effects evident in male animals included reduced size and secretion of seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, and immature prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, and testis. The administration of dasatinib resulted in <span class="product-label-link" type="condition" conceptid="4035007" conceptname="Metritis">uterine inflammation</span> and mineralization in monkeys, and cystic ovaries and ovarian <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> in rodents.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14    CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1   Newly Diagnosed Chronic Phase CML</h2>
<p class="First">An open-label, multicenter, international, randomized trial was conducted in adult patients with newly diagnosed chronic phase CML.  A total of 519 patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily.  The primary endpoint was the rate of confirmed complete cytogenetic response (CCyR) within 12 months. Confirmed CCyR was defined as a CCyR noted on two consecutive occasions (at least 28 days apart).</p>
<p>Median age was 46 years in the SPRYCEL group and 49 years in the imatinib groups, with 10% and 11% of patients ≥65 years of age. There were slightly more male than female patients in both groups (59% vs 41%). Fifty-three percent of all patients were Caucasian, and 39% were Asian. At baseline, the distribution of Hasford Scores was similar in the SPRYCEL and imatinib treatment groups (low risk: 33% and 34%; intermediate risk: 48% and 47%; high risk: 19% and 19%, respectively).</p>
<p>The median duration of treatment was 14 months for SPRYCEL and 14 months for imatinib. With a minimum of 12 months follow-up, 85% of patients randomized to SPRYCEL and 81% of patients randomized to imatinib were still on study.</p>
<p>Efficacy results are summarized in Table 6.</p>
<a name="i1832fb8c-bb8a-4044-8cfc-3474e2de592e"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 6: Efficacy Results in Newly Diagnosed Patients with Chronic Phase CML</span></caption>
<colgroup>
<col width="40%">
<col width="22%">
<col width="22%">
<col width="16%">
</colgroup>
<thead>
<tr class="First">
<th class="Toprule"> </th>
<th class="Botrule Toprule" align="center" valign="bottom">SPRYCEL<br>(n=259)</th>
<th class="Botrule Toprule" align="center" valign="bottom">Imatinib<br>(n=260)</th>
<th class="Botrule Toprule" align="center" valign="top">p-value</th>
</tr>
<tr class="Last">
<th class="Botrule"> </th>
<th class="Botrule" colspan="2">Response rate (95% CI)</th>
<th class="Botrule"> </th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="4" rowspan="1">
<span class="Sup">a</span> Confirmed CCyR is defined as a CCyR noted on two consecutive occasions at least 28 days apart.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">b</span> Major molecular response (at any time) was defined as BCR-ABL ratios ≤0.1% by RQ-PCR in peripheral blood samples standardized on the International scale.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
												*Adjusted for Hasford Score and indicated statistical significance at a pre-defined nominal level of significance.</td></tr>
<tr class="Last"><td align="left" colspan="4" rowspan="1">
												CI = confidence interval.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td>
<span class="Bold">Confirmed CCyR within 12 months</span><span class="Sup">a</span>
</td>
<td align="center" colspan="1" rowspan="1">76.8% (71.2–81.8)</td>
<td align="center" colspan="1" rowspan="1">66.2% (60.1–71.9)</td>
<td align="center" colspan="1" rowspan="1">p=0.007*</td>
</tr>
<tr class="Last">
<td>
<span class="Bold">Major Molecular Response</span><span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">52.1% (45.9–58.3)</td>
<td align="center" colspan="1" rowspan="1">33.8% (28.1–39.9)</td>
<td align="center" colspan="1" rowspan="1">p&lt;0.0001*</td>
</tr>
</tbody>
</table>
<p>Median time to confirmed CCyR was 3.1 months in 199 SPRYCEL responders and 5.6 months in 177 imatinib responders. Median time to MMR was 6.3 months in 135 SPRYCEL responders and 9.2 months in 88 imatinib responders. </p>
<p>Five patients on the dasatinib arm progressed to either accelerated phase or blast crisis while nine patients on the imatinib arm progressed to either accelerated phase or blast crisis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2   Imatinib Resistant or Intolerant CML or Ph+ ALL</h2>
<p class="First">The efficacy and safety of SPRYCEL were investigated in adult patients with CML or Ph+ ALL whose disease was resistant to or who were intolerant to imatinib: 1158 patients had chronic phase CML, 858 patients had accelerated phase, myeloid blast phase, or lymphoid blast phase CML, and 130 patients had Ph+ ALL. In a clinical study in chronic phase CML, resistance to imatinib was defined as failure to achieve a complete hematologic response (CHR; after 3 months), major cytogenetic response (MCyR; after 6 months), or complete cytogenetic response (CCyR; after 12 months); or loss of a previous molecular response (with concurrent ≥10% increase in Ph+ metaphases), cytogenetic response, or hematologic response. Imatinib intolerance was defined as inability to tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity. 
						</p>
<p>Results described below are based on a minimum of 2 years follow-up after the start of SPRYCEL therapy in patients with a median time from initial diagnosis of approximately 5 years. Across all studies, 48% of patients were women, 81% were white, 15% were black or Asian, 25% were 65 years of age or older, and 5% were 75 years of age or older. Most patients had long disease histories with extensive prior treatment, including imatinib, cytotoxic chemotherapy, interferon, and stem cell transplant. Overall, 80% of patients had imatinib-resistant disease and 20% of patients were intolerant to imatinib. The maximum imatinib dose had been 400–600 mg/day in about 60% of the patients and &gt;600 mg/day in 40% of the patients. 
						</p>
<p>The primary efficacy endpoint in chronic phase CML was MCyR, defined as elimination (CCyR) or substantial diminution (by at least 65%, partial cytogenetic response) of Ph+ hematopoietic cells. The primary efficacy endpoint in accelerated phase, myeloid blast phase, lymphoid blast phase CML, and Ph+ ALL was major hematologic response (MaHR), defined as either a CHR or no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (NEL). 
						</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2.1"></a><a name="section-13.2.1"></a><p></p>
<h3>Chronic Phase CML</h3>
<p class="First"><span class="Italics">Dose-Optimization Study:</span> A randomized, open-label study was conducted in patients with chronic phase CML to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. Patients with significant cardiac diseases, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> within 6 months, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> within 3 months, significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, or QTc prolongation were excluded from the study. The primary efficacy endpoint was MCyR in patients with imatinib-resistant CML. A total of 670 patients, of whom 497 had imatinib-resistant disease, were randomized to the SPRYCEL 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily group. Median duration of treatment was 22 months. 
									</p>
<p>Efficacy was achieved across all SPRYCEL treatment groups with the once daily schedule demonstrating comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% CI [-6.8%–10.6%]). 
								</p>
<p>Efficacy results are presented in Table 7 for patients with chronic phase CML who received the recommended starting dose of 100 mg once daily. Additional efficacy results in this patient population are described after the table. Results for all patients with chronic phase CML, regardless of dosage (a starting dosage of 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily), were consistent with those for patients treated with 100 mg once daily.
								</p>
<a name="i8c4fc8ba-a48f-495f-8bb6-7cbf5c714778"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 7: Efficacy of SPRYCEL in Imatinib Resistant or Intolerant Chronic Phase CML</span></caption>
<colgroup>
<col width="66%">
<col width="34%">
</colgroup>
<thead><tr class="First Last">
<th class="Toprule"> </th>
<th class="Toprule" align="center">
<span class="Bold">100 mg Once Daily</span><br><span class="Bold">(n=167)</span>
</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="2" rowspan="1">
<span class="Sup">a</span> CHR (response confirmed after 4 weeks):  WBC ≤  institutional ULN, platelets &lt;450,000/mm<span class="Sup">3</span>, no blasts or promyelocytes in peripheral blood, &lt;5% myelocytes plus metamyelocytes in peripheral blood, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span> in peripheral blood &lt;20%, and no extramedullary involvement.</td></tr>
<tr class="Last"><td align="left" colspan="2" rowspan="1">
<span class="Sup">b</span> MCyR combines both complete (0% Ph+ metaphases) and partial (&gt;0%–35%) responses.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1">CHR<span class="Sup">a</span>% (95% CI)</td>
<td align="center" colspan="1" rowspan="1">92% (86–95)</td>
</tr>
<tr>
<td align="left">MCyR<span class="Sup">b</span>% (95% CI)</td>
<td align="center">63% (56–71)</td>
</tr>
<tr class="Last">
<td align="left">CCyR% (95% CI)</td>
<td align="center">50% (42–58)</td>
</tr>
</tbody>
</table>
<p>In the SPRYCEL 100 mg once daily group, median time to MCyR was 2.9 months (95% CI: [2.8–3.0]).  Based on the Kaplan-Meier estimates, 93% (95% CI: [88%–98%]) of patients who had achieved an MCyR maintained that response for 18 months. The estimated rate of progression-free survival and overall survival in all patients treated with 100 mg once daily was 80% (95% CI: [73%–87%]) and 91% (95% CI: [86%–96%]), respectively, at 2 years. 
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2.2"></a><a name="section-13.2.2"></a><p></p>
<h3>Advanced Phase CML and Ph+ ALL</h3>
<p class="First"><span class="Italics">Dose-Optimization Study: </span>One randomized open-label study was conducted in patients with advanced phase CML (accelerated phase CML, myeloid blast phase CML, or lymphoid blast phase CML) to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. The primary efficacy endpoint was MaHR. A total of 611 patients were randomized to either the SPRYCEL 140 mg once daily or 70 mg twice daily group.  Median duration of treatment was approximately 6 months for both treatment groups. The once daily schedule demonstrated comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint.
									</p>
<p>The efficacy and safety of SPRYCEL were also investigated in patients with Ph+ ALL in one randomized study (starting dosage 140 mg once daily or 70 mg twice daily) and one single-arm study (starting dosage 70 mg twice daily). The primary efficacy endpoint was MaHR. A total of 130 patients were enrolled in these studies. The median duration of therapy was 3 months.</p>
<p>Response rates are presented in Table 8.
								</p>
<a name="i9b3a1357-3ecd-4c3b-8ba3-f86bac3522b8"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 8: Efficacy of SPRYCEL in Imatinib Resistant or Intolerant Advanced Phase CML and Ph+ ALL</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<th> </th>
<th class="Botrule" align="center" colspan="4"><span class="Bold">140 mg Once Daily</span></th>
</tr>
<tr class="Last">
<th> </th>
<th align="center"><span class="Bold">Accelerated<br>(n=158)</span></th>
<th align="center"><span class="Bold">Myeloid Blast<br>(n=75)</span></th>
<th align="center"><span class="Bold">Lymphoid Blast<br>(n=33)</span></th>
<th class="Lrule" align="center"><span class="Bold">Ph+ ALL<br>(n=40)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="5">
<span class="Sup">a</span> Hematologic response criteria (all responses confirmed after 4 weeks): Major hematologic response:  (MaHR) = complete hematologic response (CHR) + no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (NEL).
												<br>     CHR: WBC ≤ institutional ULN, ANC ≥1000/mm<span class="Sup">3</span>, platelets  ≥100,000/mm<span class="Sup">3</span>, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤5%, &lt;5% myelocytes plus metamyelocytes in peripheral blood, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span> in peripheral blood &lt;20%, and no extramedullary involvement.
												<br>      NEL: same criteria as for CHR but ANC ≥500/mm<span class="Sup">3</span> and &lt;1000/mm<span class="Sup">3</span>, or platelets ≥20,000/mm<span class="Sup">3</span> and ≤100,000/mm<span class="Sup">3</span>.</td></tr>
<tr><td colspan="5">
<span class="Sup">b</span> MCyR  combines both complete (0% Ph+ metaphases) and partial (&gt;0%–35%) responses.</td></tr>
<tr class="Last"><td colspan="5">CI = confidence interval     ULN = upper limit of normal range.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td>
<span class="Bold">MaHR</span><span class="Sup">a</span>
</td>
<td align="center">66%</td>
<td align="center">28%</td>
<td align="center">42%</td>
<td class="Lrule" align="center">38%</td>
</tr>
<tr>
<td>          (95% CI)</td>
<td align="center">(59–74)</td>
<td align="center">(18–40)</td>
<td align="center">(26–61)</td>
<td class="Lrule" align="center">(23–54)</td>
</tr>
<tr>
<td>     CHR<span class="Sup">a</span>
</td>
<td align="center">47%</td>
<td align="center">17%</td>
<td align="center">21%</td>
<td class="Lrule" align="center">33%</td>
</tr>
<tr>
<td>          (95% CI)</td>
<td align="center">(40–56)</td>
<td align="center">(10–28)</td>
<td align="center">(9–39)</td>
<td class="Lrule" align="center">(19–49)</td>
</tr>
<tr>
<td>     NEL<span class="Sup">a</span>
</td>
<td align="center">19%</td>
<td align="center">11%</td>
<td align="center">21%</td>
<td class="Lrule" align="center">5%</td>
</tr>
<tr>
<td class="Botrule">          (95% CI)</td>
<td class="Botrule" align="center">(13–26)</td>
<td class="Botrule" align="center">(5–20)</td>
<td class="Botrule" align="center">(9–39)</td>
<td class="Botrule Lrule" align="center">(1–17)</td>
</tr>
<tr>
<td>
<span class="Bold">MCyR</span><span class="Sup">b</span>
</td>
<td align="center">39%</td>
<td align="center">28%</td>
<td align="center">52%</td>
<td class="Lrule" align="center">70%</td>
</tr>
<tr>
<td>          (95% CI)</td>
<td align="center">(31–47)</td>
<td align="center">(18–40)</td>
<td align="center">(34–69)</td>
<td class="Lrule" align="center">(54–83)</td>
</tr>
<tr>
<td>     CCyR</td>
<td align="center">32%</td>
<td align="center">17%</td>
<td align="center">39%</td>
<td class="Lrule" align="center">50%</td>
</tr>
<tr class="Last">
<td>          (95% CI)</td>
<td align="center">(25–40)</td>
<td align="center">(10–28)</td>
<td align="center">(23–58)</td>
<td class="Lrule" align="center">(34–66)</td>
</tr>
</tbody>
</table>
<p>In the SPRYCEL 140 mg once daily group, the median time to MaHR was 1.9 months for patients with accelerated phase CML, 1.9 months for patients with myeloid blast phase CML, and 1.8 months for patients with lymphoid blast phase CML.
								</p>
<p>In patients with myeloid blast phase CML, the median duration of MaHR was 8 months and 9 months for the 140 mg once daily group and the 70 mg twice daily group, respectively. In patients with lymphoid blast phase CML, the median duration of MaHR was 5 months and 8 months for the 140 mg once daily group and the 70 mg twice daily group, respectively. In patients with Ph+ ALL who were treated with SPRYCEL 140 mg once daily, the median duration of MaHR was 4.6 months. The medians of progression-free survival for patients with Ph+ ALL treated with SPRYCEL 140 mg once daily and 70 mg twice daily were 4.0 months and 3.5 months, respectively.
								</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_15"></a><a name="section-14"></a><p></p>
<h1>15    REFERENCES </h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004–165.
							</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999, <a href="http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</a>. 
							</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm. </span>(2006) 63:1172–1193.
							</li>
<li>Polovich M, White JM, Kelleher LO (eds). 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed). Pittsburgh, PA: Oncology Nursing Society. 
							</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16    HOW SUPPLIED/STORAGE AND HANDLING </h1>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.1   How Supplied</h2>
<p class="First">SPRYCEL<span class="Sup">®</span> (dasatinib) tablets are available as described in Table 9.</p>
<a name="i183e7d31-c7ac-4580-8c45-af56cbd16e8e"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 9: SPRYCEL Trade Presentations</span></caption>
<colgroup>
<col width="20%">
<col width="15%">
<col width="50%">
<col width="15%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">NDC Number</span></td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Strength</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Description</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Tablets per Bottle</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" colspan="1" rowspan="1">54868-5759-0</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">70 mg</td>
<td class="Botrule Lrule Rrule" align="center" colspan="1" rowspan="1">white to off-white, biconvex, round, film-coated tablet with “BMS? debossed on one side and “524? on the other side</td>
<td class="Botrule Rrule" align="center" colspan="1" rowspan="1">60</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16.2"></a><a name="section-15.2"></a><p></p>
<h2>16.2   Storage</h2>
<p class="First">SPRYCEL<span class="Sup">®</span> tablets should be stored at 20° to 25°C (68° to 77°F); excursions permitted between 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.3"></a><a name="section-15.3"></a><p></p>
<h2>16.3   Handling and Disposal</h2>
<p class="First">Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject
have been published <span class="Italics">[see References <a href="#Section_15">(15)</a>]</span>. 
</p>
<p>SPRYCEL (dasatinib) tablets consist of a core tablet (containing the active drug substance), surrounded by a film coating to prevent exposure of pharmacy and clinical personnel to the active drug substance. However, if tablets are inadvertently crushed or broken, pharmacy and clinical personnel should wear disposable chemotherapy gloves. Personnel who are pregnant should avoid exposure to crushed or broken tablets.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17    PATIENT COUNSELING INFORMATION </h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Patients should be informed of the possibility of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and to report immediately any signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>).
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-16.2"></a><p></p>
<h2>17.2   <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Patients should be informed of the possibility of developing low blood cell counts; they should be instructed to report immediately should <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> develop, particularly in association with any suggestion of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-16.3"></a><p></p>
<h2>17.3   <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Patients should be informed of the possibility of developing <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>)
and to seek medical attention if those symptoms arise.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-16.4"></a><p></p>
<h2>17.4   Pregnancy</h2>
<p class="First">Patients should be informed that dasatinib may cause fetal harm when administered to a pregnant woman. Women should be advised of the potential hazard to the fetus and to avoid becoming pregnant. If SPRYCEL is used during pregnancy, or if the patient becomes pregnant while taking SPRYCEL, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see Warnings and Precautions <a href="#Section_5.7">(5.7)</a>]</span>.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-16.5"></a><p></p>
<h2>17.5   Gastrointestinal Complaints</h2>
<p class="First">Patients should be informed that they may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with SPRYCEL. If these symptoms
are significant, they should seek medical attention.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.6"></a><a name="section-16.6"></a><p></p>
<h2>17.6   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></h2>
<p class="First">Patients should be informed that they may experience <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span> with SPRYCEL. If these symptoms are significant, they should seek medical attention.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.7"></a><a name="section-16.7"></a><p></p>
<h2>17.7   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></h2>
<p class="First">Patients should be informed that they may experience <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> with SPRYCEL. If this symptom is significant, they should seek medical attention.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.8"></a><a name="section-16.8"></a><p></p>
<h2>17.8   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">Patients should be informed that they may experience <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> with SPRYCEL. If this symptom is significant, they should seek medical attention.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.9"></a><a name="section-16.9"></a><p></p>
<h2>17.9   Lactose</h2>
<p class="First">Patients should be informed that SPRYCEL contains 135 mg of lactose monohydrate in a 100-mg daily dose and 189 mg of lactose monohydrate in a 140-mg daily dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.10"></a><a name="section-16.10"></a><p></p>
<h2>17.10   Missed Dose</h2>
<p class="First">If the patient misses a dose of SPRYCEL, the patient should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_18.0"></a><a name="section-17"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.1"></a><a name="section-17.1"></a><p></p>
<h2>FDA-Approved Patient Labeling</h2>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">SPRYCEL</span><span class="Sup">®</span><span class="Bold"> (Spry-sell)</span></p>
<p><span class="Bold">(dasatinib)</span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read the Patient Information that comes with SPRYCEL before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is SPRYCEL?</span></p>
<p>SPRYCEL<span class="Sup">®</span> is a prescription medicine used to treat adults who have:
										</p>
<ul class="Disc">
<li>newly diagnosed Philadelphia chromosome-positive (Ph+) <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) in chronic phase.</li>
<li>Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including Gleevec<span class="Sup">®</span> (imatinib mesylate).</li>
<li>Philadelphia chromosome-positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment.</li>
</ul>
<p>It is not known if SPRYCEL is safe and effective in children younger than 18 years old.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking SPRYCEL?</span></p>
<p><span class="Bold">Before you take SPRYCEL, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have problems with your immune system</li>
<li>have liver problems</li>
<li>have heart problems</li>
<li>are lactose intolerant</li>
<li>have any other medical conditions</li>
<li>are pregnant or planning to become pregnant. SPRYCEL may harm your unborn baby. Women should not become pregnant while taking SPRYCEL. Talk to your healthcare provider right away if you are pregnant or plan to become pregnant.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if SPRYCEL passes into your breast milk or if it can harm your baby. You and your healthcare provider should decide if you will take SPRYCEL or breastfeed.  You should not do both.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, antacids, and herbal supplements.</span></p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<ul class="Disc"><li><span class="Bold">medicines that increase the amount of SPRYCEL in your bloodstream, such as:</span></li></ul>
<a name="ic3810b46-7457-4bf8-8d4f-8e3ac83a90d8"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<colgroup>
<col width="5%">
<col width="45%">
<col width="45%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First Norule">
<td align="left"> </td>
<td align="left">Nizoral<span class="Sup">®</span> (ketoconazole),</td>
<td align="left">Nefazodone (serzone, nefadar),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Sporanox<span class="Sup">®</span> (itraconazole),</td>
<td align="left">Invirase<span class="Sup">®</span> (saquinavir),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Norvir<span class="Sup">®</span> (ritonavir),</td>
<td align="left">Ketek<span class="Sup">®</span> (telithromycin),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Reyataz<span class="Sup">®</span> (atazanavir sulfate),</td>
<td align="left">E-mycin<span class="Sup">®</span> (erythromycin),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Crixivan<span class="Sup">®</span> (indinavir),</td>
<td align="left">Biaxin<span class="Sup">®</span> (clarithromycin).</td>
<td align="left"> </td>
</tr>
<tr class="Last Norule">
<td align="left"> </td>
<td align="left">Viracept<span class="Sup">®</span> (nelfinavir),</td>
<td align="left"> </td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<ul class="Disc"><li><span class="Bold">medicines that decrease the amount of SPRYCEL in your bloodstream, such as:</span></li></ul>
<a name="i6603ec8f-e42f-4453-8406-f266f6f67188"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<colgroup>
<col width="5%">
<col width="45%">
<col width="45%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First Norule">
<td align="left"> </td>
<td align="left">Decadron<span class="Sup">®</span> (dexamethasone),</td>
<td align="left">Rimactane<span class="Sup">®</span> (rifampin),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Dilantin<span class="Sup">®</span> (phenytoin),</td>
<td align="left">Luminal<span class="Sup">®</span> (phenobarbital).</td>
<td align="left"> </td>
</tr>
<tr class="Last Norule">
<td align="left"> </td>
<td align="left">Tegretol<span class="Sup">®</span> (carbamazepine),</td>
<td align="left"> </td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<ul class="Disc"><li><span class="Bold">medicines whose blood levels might change by taking SPRYCEL, such as:</span></li></ul>
<a name="i89124cbe-37e8-4e40-8436-46dd2624ac83"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<colgroup>
<col width="5%">
<col width="45%">
<col width="45%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First Norule">
<td align="left"> </td>
<td align="left">Sandimmune<span class="Sup">®</span> (cyclosporine),</td>
<td align="left">Rapamune<span class="Sup">®</span> (sirolimus),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Alfenta<span class="Sup">®</span> (alfentanil),</td>
<td align="left">Prograf<span class="Sup">®</span> (tacrolimus),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Fentanyl<span class="Sup">®</span> (fentanyl),</td>
<td align="left">Ergomar<span class="Sup">®</span> (ergotamine).</td>
<td align="left"> </td>
</tr>
<tr class="Last Norule">
<td align="left"> </td>
<td align="left">Orap<span class="Sup">®</span> (pimozide),</td>
<td align="left"> </td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<p><span class="Bold">SPRYCEL is best absorbed from your stomach into your bloodstream in the presence of stomach acid.  You should avoid taking medicines that reduce stomach acid, such as: </span></p>
<a name="iab8138e8-2218-4998-8447-b041662c507b"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<colgroup>
<col width="5%">
<col width="45%">
<col width="45%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First Norule">
<td align="left"> </td>
<td align="left">Tagamet<span class="Sup">®</span> (cimetidine),</td>
<td align="left">Protonix<span class="Sup">®</span> (pantoprazole sodium),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Pepcid<span class="Sup">®</span> (famotidine),</td>
<td align="left">Nexium<span class="Sup">®</span> (esomeprazole),</td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Zantac<span class="Sup">®</span> (ranitidine),</td>
<td align="left">AcipHex<span class="Sup">®</span> (rabeprazole),</td>
<td align="left"> </td>
</tr>
<tr class="Last Norule">
<td align="left"> </td>
<td align="left">Prilosec<span class="Sup">®</span> (omeprazole),</td>
<td align="left">Prevacid<span class="Sup">®</span> (lansoprazole).</td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<p><span class="Bold">Medicines that neutralize stomach acid, such as</span> Maalox<span class="Sup">®</span> (aluminum hydroxide/magnesium hydroxide), Tums<span class="Sup">®</span> (calcium carbonate), or Rolaids<span class="Sup">®</span> (calcium carbonate and magnesia), may be taken up to 2 hours before or 2 hours after SPRYCEL.

</p>
<p><span class="Bold">Since SPRYCEL therapy may cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span>, tell your healthcare provider if you are using blood thinner medicine, such as Coumadin<span class="Sup">®</span> (warfarin sodium) or aspirin. </p>
<p><span class="Bold">Know the medicines you take.</span> Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How should I take SPRYCEL?</span></p>
<p><span class="Bold">Take SPRYCEL exactly as prescribed by your healthcare provider.</span></p>
<ul class="Disc">
<li>Take SPRYCEL with or without food. Try to take SPRYCEL at the same time each day.</li>
<li>Swallow SPRYCEL tablets whole. Do not break, cut, or crush the tablets.</li>
<li>You should not drink grapefruit juice while taking SPRYCEL.</li>
<li>
<span class="Bold">Your healthcare provider may:</span><ul class="Disc">
<li><span class="Bold">change your dose of SPRYCEL or</span></li>
<li><span class="Bold">tell you to temporarily stop taking SPRYCEL. </span></li>
</ul>
</li>
<li><span class="Bold">Do not change your dose or stop taking SPRYCEL without first talking with your healthcare provider.</span></li>
<li>
<span class="Bold">If you miss a dose of SPRYCEL</span>, take your next scheduled dose at its regular time. Do not take two doses at the same time. Call your healthcare provider or pharmacist if you are not sure what to do.</li>
<li>
<span class="Bold">If you take too much SPRYCEL</span>, call your healthcare provider or go to the nearest hospital emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of SPRYCEL?</span></p>
<p><span class="Bold">SPRYCEL may cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Low Blood Cell Counts:</span> SPRYCEL may cause low red blood cell counts (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), low white blood cell counts (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), and low platelet counts (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>).  Your healthcare provider will do blood tests to check your blood cell counts regularly during your treatment with SPRYCEL. Call your healthcare provider right away if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or any signs of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while taking SPRYCEL.
											</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>:</span> SPRYCEL may cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your healthcare provider right away if you have:
											<ul class="Disc">
<li>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> of your skin</li>
<li>bright red or dark tar-like stools</li>
<li>a decrease in your level of consciousness, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, or change in speech.</li>
</ul>
</li>
<li>
<span class="Bold">Your body may hold too much fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>):</span> In severe cases, fluid may build up in the lining of your lungs, the sac around your heart, or your stomach cavity. Call your healthcare provider right away if you get any of these symptoms during treatment with SPRYCEL:
											<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> all over your body</li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</li>
</ul>
</li>
<li>
<span class="Bold">Heart problems.</span> SPRYCEL may cause an abnormal heart rate, heart problems or a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. It may also cause changes in the blood vessels supplying the lungs. Your healthcare provider will monitor the potassium and magnesium levels in your blood, and your heart function.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span> (PAH).</span> SPRYCEL may cause high blood pressure in the vessels of your lungs. PAH may happen at anytime during your treatment with SPRYCEL. Your healthcare provider should check your heart and lungs before and during your treatment with SPRYCEL. Call your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> all over your body (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>).</li>
</ul>
<p>Other common side effects of SPRYCEL therapy include:</p>
<a name="if37894ab-5c2c-408a-8458-cac74631308c"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<colgroup>
<col width="5%">
<col width="45%">
<col width="45%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First Norule">
<td align="left"> </td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></td>
<td align="left"> </td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td align="left"> </td>
</tr>
<tr class="Last Norule">
<td align="left"> </td>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td align="left"> </td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of SPRYCEL. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store SPRYCEL?</span></p>
<ul class="Disc">
<li>Store SPRYCEL at room temperature, between 68°F to 77°F (20°C to 25°C).</li>
<li>Ask your healthcare provider or pharmacist about the right way to throw away outdated or unused SPRYCEL.</li>
<li>Women who are pregnant should not handle crushed or broken SPRYCEL tablets.</li>
<li><span class="Bold">Keep SPRYCEL and all medicines out of the reach of children and pets.</span></li>
</ul>
<p><span class="Bold">General information about SPRYCEL</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use SPRYCEL for a condition for which it is not prescribed. Do not give SPRYCEL to other people even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about SPRYCEL. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about SPRYCEL that is written for healthcare professionals.</p>
<p>For more information, go to www.sprycel.com or call 1-800-332-2056. </p>
<p><span class="Bold">What are the ingredients in SPRYCEL?</span></p>
<p><span class="Bold">Active ingredient: </span> dasatinib</p>
<p><span class="Bold">Inactive ingredients:</span> lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium dioxide, and polyethylene glycol.</p>
<p></p>
<p><span class="Bold">This Patient Package Insert has been approved by the U.S. Food and Drug Administration.</span></p>
<p></p>
<p></p>
<p>Manufactured by:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA</p>
<p></p>
<p></p>
<p>Revised: October 2011</p>
<p></p>
<p></p>
<p>Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA</p>
<p></p>
<p>1284903A0<br>Rev October 2011</p>
<p></p>
<p>Additional barcode labeling by:</p>
<p>Physicians Total Care, Inc.</p>
<p>Tulsa, Oklahoma        74146</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span>NDC 54868-5759-0 <br></span></p>
<p><span>60 tablets</span></p>
<p><img alt="image of 70 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f&amp;name=5759.jpg"></p>
<p><span>SPRYCEL<span class="Sup">®</span><br>(dasatinib)
					 <br>Tablets
					 <br>70 mg
					 <br>Rx only
					 <br>Do not crush or cut tablet
					 <br></span></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SPRYCEL
                         		
					</strong><br><span class="contentTableReg">dasatinib tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5759(NDC:0003-0524)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dasatinib</strong> (dasatinib) </td>
<td class="formItem">dasatinib</td>
<td class="formItem">70 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BMS;524</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5759-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021986</td>
<td class="formItem">02/12/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fa3f43fa-ff9a-49ae-9127-3a141af355d4</div>
<div>Set id: 0e7f054c-7a27-4192-bd1c-6115d8be858f</div>
<div>Version: 1</div>
<div>Effective Time: 20120601</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
